Back to Search
PATRICK KWON, M.D.
M.D.
Neuromuscular Medicine (Psychiatry & Neurology) Physician
NPI: 1558669812IndividualAccepts Medicare
Specialties, Licenses & Credentials
Neurology Physician
Psychiatry & Neurology — Neurology
Code: 2084N0400X
270621(NY)
Neuromuscular Medicine (Psychiatry & Neurology) PhysicianPrimary
Psychiatry & Neurology — Neuromuscular Medicine
Code: 2084N0008X
270621(NY)
CMS Specialties
PrimaryNEUROLOGY
Education
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
Class of 2010
Research & Publications (20)
Compatibility of imported fire ant whole body extract with cat, ragweed, Dermatophagoides pteronyssinus, and timothy grass allergens.
PMID 19205287·Ann Allergy Asthma Immunol·2009
7-preclinical
Coumarin-derived Cu(2+)-selective fluorescence sensor: synthesis, mechanisms, and applications in living cells.
PMID 19191706·J Am Chem Soc·2009
7-preclinical
In vitro and in vivo photodynamic therapy of otitis media in gerbils.
PMID 19572273·Laryngoscope·2009
7-preclinical
Chromofluorescent indicator for intracellular Zn2+/Hg2+ dynamic exchange.
PMID 18681453·Org Lett·2008
7-preclinical
[Detection of rifampin resistant mycobacterium tuberculosis complex using denaturing HPLC].
PMID 18458504·Korean J Lab Med·2008
8-other
Neonatal extrapyramidal movements. Neonatal withdrawal due to maternal citalopram and ondansetron use.
PMID 18411854·Pediatr Ann·2008
5-case
Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers.
PMID 18210954·J Wound Care·2008
3-trial
Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study.
PMID 17550570·Int J Dermatol·2007
3-trial
4-1BB triggers IL-13 production from T cells to limit the polarized, Th1-mediated inflammation.
PMID 17389581·J Leukoc Biol·2007
7-preclinical
Blockade of the 4-1BB (CD137)/4-1BBL and/or CD28/CD80/CD86 costimulatory pathways promotes corneal allograft survival in mice.
PMID 17376197·Immunology·2007
7-preclinical
Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial.
PMID 16488337·J Am Acad Dermatol·2006
3-trial
A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis.
PMID 17033169·Dermatology·2006
4-observational
Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis.
PMID 16488338·J Am Acad Dermatol·2006
3-trial
An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis.
PMID 16397279·J Clin Pharmacol·2006
6-review
Maintenance of osseointegration utilizing insulin therapy in a diabetic rat model.
PMID 15857104·J Periodontol·2005
7-preclinical
Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I.
PMID 16699904·J Cutan Med Surg·2005
4-observational
Immune thrombocytopenia associated with efalizumab therapy for psoriasis.
PMID 16287807·Ann Intern Med·2005
8-other
Management and outcomes of intracranial tuberculomas developing during antituberculous therapy: case report and review.
PMID 15965552·Clin Pediatr (Phila)·2005
5-case
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 8714 5TH AVE
BROOKLYN, NY 11209 - Phone
- (718) 630-8600
Quick Facts
- NPI
- 1558669812
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 2
- Years in Practice
- 16
- Publications
- 20
Are you this provider?
Claim Your Profile